Sex Transm Dis by Dionne-Odom, Jodie et al.
Antimicrobial Resistant Gonorrhea in Atlanta: 1988 – 2006
Jodie Dionne-Odom, MD*, Pradnya Tambe, MD˘, Eileen Yee, MD°, Hillard Weinstock, MD,
MPH°, and Carlos del Rio, MD@
* Section of Infectious Disease and International Health, Dartmouth Medical School, Dartmouth-
Hitchcock Medical Center, Lebanon, New Hampshire
˘ Fulton County Department of Health and Wellness STD Clinic, Atlanta, Georgia
° Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta, Georgia
@ Hubert Department of Global Health, Rollins School of Public Health of Emory University,
Atlanta, Georgia
Abstract
Gonococcal isolates (n = 4336) were collected from men with urethritis at the Fulton County STD
Clinic from 1988 – 2006. Antimicrobial susceptibility was performed by agar dilution. Increasing
numbers of isolates from MSM and with fluoroquinolone resistance were noted. New
antimicrobials effective against gonorrhea are urgently needed.
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Gonorrhea is the second most commonly reported sexually transmitted disease (STD) in the
United States. According to the 2008 STD Surveillance data from CDC, the rate for
gonorrhea in the US was 112 cases per 100,000 population. Although rates over the past ten
years have been generally stable, geographically, the South has always had the highest
gonorrhea rates in the country. In 2008, the state of Georgia had the 6th highest case rate for
gonorrhea nationwide (171 cases/100,000 population). Fulton County, which includes most
of Atlanta, had a rate of 297 cases/100,000 population [1].
National monitoring of antimicrobial resistance in Neisseria gonorrhoeae in the United
States has been possible since 1986 under the auspices of the CDC sponsored Gonococcal
Isolate Surveillance Project (GISP), a sentinel surveillance project conducted at 25–30 sites.
It was established to monitor trends in antimicrobial susceptibility of gonococcal isolates
from men with urethritis and described elsewhere [2]. Details of laboratory procedures and
data collection can be accessed online at www.cdc.gov/std/gisp as well as in the CDC GISP
annual report [3]. The emergence of fluoroquinolone resistance (QRNG) in the US, as
documented by GISP, has been reviewed by Fox et al (1988–1994), and Wang et al (1988–
2003) [4–6].
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The purpose of the current analysis is to document antimicrobial resistance in N.
gonorrhoeae, demographic characteristics and describe the trends in antibiotics used to treat
gonococcal urethral infections at the Fulton County Department of Health and Wellness
(FCDHW) STD Clinic from 1988–2006.
Linear regression was used to assess the trend of age over time and Kruskal-Wallis test was
used for the association of age with QRNG. To test the trend of MSM as a categorical
variable over time, the Cochran-Armitage test was used. Chi-squared test was used to look
for an association between QRNG and age (dichotomized as younger than 30 or 30 and
older). Geometric mean was calculated for each year of MIC data for azithromycin. Data
analyses were performed using SAS Enterprise Guide 4.
Antimicrobial susceptibilities were determined for all samples by the Emory University
GISP regional laboratory using agar dilution methods and MICs were interpreted according
to the most recent Clinical Laboratory Standards Institute (CLSI) breakpoints published in
January 2007 [7]. Ciprofloxacin resistance is defined as MIC ≥ 1 μg/mL with intermediate
resistance at MIC 0.125–0.5 μg/ml. There are no CLSI guidelines that define azithromycin
susceptibility or resistance, but criteria from the GISP protocol lists the decreased
susceptibility cutoff at MIC ≥1 μg/mL. In 2005, this cutoff for decreased susceptibility was
changed to ≥ 2 μg/mL due to a change in media. [8]
There were 4,336 isolates collected from 1988–2006 for the FCDHW STD Clinic as part of
GISP. Patient characteristics are listed in Table 1. Men who reported only having sex with
men increased significantly over the study period from 1% in 1996 to 9% in 2006
(p=0.0001). The percent that were bisexual also increased from 0.5% in 1996 to 3.7% in
2006 (p=0.02) (Figure 1 shows homosexual and bisexual rates combined as MSM rates).
Data on HIV prevalence has been captured for a subset of GISP Fulton County clients since
2002 and has averaged 4.8% over five years. HIV prevalence was 31% among MSM
(26/84), and 1% (9/633) among men who denied having had sex with men. Many patients
(35.8% to 60% each year) had a previous history of gonococcal infection and, when
stratified by age, this was more common among ages 18–25 relative to older males.
In terms of changing gonorrhea treatment patterns, ampicillin or amoxicillin was prescribed
for 89% of patients in 1988, then ceftriaxone for 85% in 1989–1990. From 1991–1994, oral
ofloxacin 400 mg was given to most patients (range 48%–84% of treated patients). Since
1996, ceftriaxone 125 mg intramuscular has been the drug of choice for prescribers although
the dosage of 250 mg IM was given more frequently from 1998–2001. Fluoroquinolones
have been used minimally to treat gonorrhea since 1996, ranging from 0–1.6% of all
antibiotics prescribed for gonococcal infections. Spectinomycin has not been given since
2001. Only fifteen patients of this group received two grams of azithromycin and one patient
received doxycycline as gonorrhea therapy between 2002 and 2006.
There were 25 cases of QRNG documented from 1988–2006, insufficient cases for an
analysis of risk factors based on sexual orientation or HIV status. Among the clients with
QRNG, 28% reported having sex with men and 4% were HIV infected. There was sufficient
data to consider age as a risk factor for QRNG, but there was no association noted.
Intermediate resistance to ciprofloxacin was first noted in an isolate from 1997, it peaked at
5.3% in 1999 and then disappeared after 2002. In 1997, and again in 2004, one isolate was
noted to have high level resistance to ciprofloxacin (MIC 1 μg/ml and MIC 2 μg/ml,
respectively). QRNG prevalence subsequently increased to 3.8% in 2005 and 5.7% in 2006.
(Figure 2) In 2006, 36% of the QRNG had an MIC 16 μg/ml or greater.
Azithromycin has been included in the panel of antibiotics tested since 1997. Among the
isolates tested, decreased susceptibility was first noted in two isolates during 2000. By 2004,
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6% (7/116) of isolates tested had decreased azithromycin susceptibility (MIC 1–4 μg/ml)
(Fig 3). Presence of β-lactamase in sampled N. gonorrhoeae isolates peaked in 1990 and has
been stable at minimal levels since 2003 (range 0.4–1.2%). Similarly, resistance to penicillin
has been present at levels ranging from 1–8% over the past five years. Chromosomally
mediated resistance to tetracycline (MIC 2–8 μg/ml) peaked at 41% in 1995 and now ranges
from 4–11% while the plasmid mediated high level resistance (MIC ≥16 μg/ml) peaked later
(18% in 1998) and is seen in approximately 5% of samples from 2004–2006. There is no
documented resistance to spectinomycin from 1988–2006. For the cephalosporins, there
have been no isolates with documented resistance to ceftriaxone during the study period,
although a single isolate had decreased susceptibility to cefixime in 1992 (MIC 0.5 μg/ml).
This sentinel surveillance data from Fulton County shows the rapid introduction and spread
of fluoroquinolone resistance and increases in azithromycin geometric mean titers since
1997. Age was not associated with QRNG but MSM were more likely to have QRNG than
heterosexual men although the total number of QRNG cases was small and did not permit
statistical analysis. This association of MSM with QRNG has been shown in previous
studies [9]. There are a wide variety of reported QRNG rates nationally, from 23% in Los
Angeles, 44% in San Francisco, 4.1% in Chicago and 1.4% in Baltimore [10]. Reports of
case clusters of GC with decreased susceptibility to azithromycin are concerning (33 cases
were reported in Kansas City from 1999–2000) and national GISP data from 2003–2006
also shows increasing MICs for azithromycin.[10, 11].
In the absence of fluoroquinolones, there had been no available oral treatment options for
uncomplicated urogenital gonococcal infections until April 2008, when cefixime (400 mg
PO) once again became available [12]. Newly updated 2010 STD Treatment Guidelines
recommend ceftriaxone 250 mg intramuscular in addition to azithromycin 1 gram orally or
oral doxycycline 100 mg twice daily for seven days to treat uncomplicated gonorrhea
infection. [13] Sporadic Neisseria gonorrhoeae isolates with decreased susceptibility to
cefixime, ceftriaxone, and azithromycin have been reported and reports of clinical failure are
increasing [11, 13, 14].
Gonorrhea is a commonly reported infection in Fulton County and rates in the South have
always been the highest in the nation [3, 15]. The fact that 4.8% have HIV infection and 6–
18% had prior episodes of gonorrhea suggest ongoing high risk behaviors among this
population. These findings are similar to a study of HIV testing in Atlanta that included
1,495 FCHD patients and documented 1.9% HIV prevalence [16]. In addition, the
percentage of self-reported MSM has drastically increased from 1% to 13% for the Fulton
County GISP subset from 1996–2006. Further efforts are needed to prevent sexually
transmitted infections among MSM.
Limitations of the study include generalizability of the findings to women (since only males
participate in GISP) and persons who may have less risky sexual practices. Findings may not
be representative of all patients with gonorrhea in Fulton County, other STD clinics, or other
GISP sites. Insufficient data were collected on individual and community level antibiotic
usage to account for its contribution to resistance patterns. Collection of sexual orientation
data is limited by reporting bias and HIV status information has only been collected since
2002.
Gonorrhea continues to challenge our public health system in its persistence and increasing
antimicrobial resistance profile. The ability to identify antimicrobial resistance in isolates of
N. gonorrheae is increasingly problematic since most clinical laboratories now rely on non-
culture based methods for diagnosis which do not allow for antimicrobial susceptibility
testing. Cephalosporins remain the recommended treatment, but newer therapies are
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urgently needed in light of recent reports of decreased susceptibility to cefixime and
treatment failures as well as increased MIC’s for azithromycin. Providers should have a high
suspicion for potential treatment failure after treatment of gonorrhea and these cases should
be brought to the attention of local health authorities so that suspicious isolates can be
further investigated and antimicrobial susceptibility testing performed.
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Figure 1. Percent of isolates obtained from men who report sex with men (MSM1) in GISP
FCDHW2, 1988–2006
1MSM = men self identifying as homosexual or bisexual
2 FCDHW = Fulton County Department of Health and Wellness
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Figure 2. Intermediate susceptibility and resistance to ciprofloxacin in isolates from FCDHW1 in
GISP, 1997–2006
Note: Intermediate susceptibility is defined as MIC 0.125–0.5 μg/ml
Resistance to ciprofloxacin is defined as MIC ≥ 1 μg/ml
1 FCDHW = Fulton County Department of Health and Wellness
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Figure 3. Geometric mean trend of MICs for azithromycin, in GISP, FCDHW1, 1997–2006
1 FCDHW = Fulton County Department of Health and Wellness
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Table 1
Characteristics of FCDHW1 Males Sampled by GISP, 1988–2006
N (%)
Race/Ethnicity (n=4256)
 African-American 4186 (98.3)
 White 54 (1.2)
 Asian/Pacific Islander 12 (0.3)
 Hispanic 4 (0.1)
Age Groups (years) (n=4269)
 10–19 643 (15.1)
 20–29 1897 (44.4)
 30–39 1043 (24.4)
 40+ 686 (16.1)
Sexual Orientation (n=4113)
 Heterosexual 3893 (94.6)
 Homosexual 135 (3.3)
 Bisexual 85 (2.1)
HIV Status* (n=732)
 Positive 35 (4.8)
 Negative 687 (93.9)
 Indeterminate 10 (1.4)
Reason for Presentation (n=4172)
 Volunteer 4105 (98.4)
 Contact 44 (1.0)
 Test of Cure 13 (0.3)
 Other 10 (0.2)
History of GC (ever) ^ (n=3092)
 Yes 1688 (54.6)
 No 1404 (45.4)
Episodes GC past 12 mo† (n=1686)
 0 994 (59.0)
 1 297 (17.6)
 2–9 395 (23.4)
1
FCDHW = Fulton County Department of Health and Wellness
*
HIV Status – data available for 2002–2006 only. Most current HIV status known at the time of clinic visit for gonorrhea.
^
History of GC – data available after 1991
†
Episodes of GC – data available after 1992
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